Clinical Trial Update: TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC [Phase 2, Phase 3]

View source ↗

Summary

A neoadjuvant trial combining transarterial chemoembolization/hemorrheology-assisted interventional therapy with lenvatinib and sintilimab is being explored for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Third Affiliated Hospital, Sun Yat-Sen University | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN